Lexicon Q4 net loss narrows to $15.5M; cash strengthened with $106.7M added in Feb 2026

LEXICON PHARMACEUTICALS, INC.

Q4 net loss $15.5M ($0.04/share) vs $33.8M loss ($0.09/share) in Q4 2024; full-year loss $50.3M.
Q4 revenue $5.5M including $4.3M licensing from Novo Nordisk and $1.1M INPEFA sales.
Cash, investments, restricted cash $125.2M at Dec 31, 2025; $96.7M capital raise + $10M Novo milestone in Feb 2026.
SONATA-HCM enrollment >50% of 500 patients; on track for mid-2026 completion and Q1 2027 topline.
NDA resubmission for ZYNQUISTA in T1D on track for 2026; positive End-of-Phase 2 meeting for pilavapadin.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

LEXICON PHARMACEUTICALS, INC. reported the three months and year ended December 31, 2025 results: revenue $5.5 million and $49.8 million for the quarter and year ended December 31, 2025, respectively.

Period: the three months and year ended December 31, 2025
Revenue: $5.5 million and $49.8 million for the quarter and year ended December 31, 2025, respectively
Result: reported results

Exact text from the filing

LEXICON PHARMACEUTICALS REPORTS FOURTH QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CLINICAL UPDATES

View on SEC.gov

Browse all earnings releases →

LEXICON PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001062822-26-000047

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.